7,7-Dichloro-11,11-dimethyl-5-oxa-3lambda6-thia-4-azatetracyclo[6.2.1.01,6.04,6]undecane 3,3-dioxide | 127184-05-8

• 物质功能分类: 化学试剂 - 手性化学试剂
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 7,7-Dichloro-11,11-dimethyl-5-oxa-3lambda6-thia-4-azatetracyclo[6.2.1.01,6.04,6]undecane 3,3-dioxide
• 英文别名: 7,7-dichloro-11,11-dimethyl-5-oxa-3λ6-thia-4-azatetracyclo[6.2.1.01,6.04,6]undecane 3,3-dioxide
• CAS: 127184-05-8
• 化学式: C₁₀H₁₃Cl₂NO₃S
• 分子量: 298.19
• InChiKey: HAMBQYFZDBYWHU-UHFFFAOYSA-N

物化性质

• 熔点：
  181-186 °C
• 沸点：
  390.5±52.0 °C(Predicted)
• 密度：
  1.68±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  5.1
• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 包装等级：
  III
• 危险类别：
  5.1
• 危险品运输编号：
  UN 1479
• 危险性防范说明：
  P220,P261,P305+P351+P338
• 危险性描述：
  H271,H315,H319,H335

文献信息

• [EN] TRIOXACARCIN ANALOGS AND DIMERS AS POTENT ANTICANCER AGENTS<br/>[FR] ANALOGUES ET DIMÈRES DE TRIOXACARCINE EN TANT QU'AGENTS ANTICANCÉREUX PUISSANTS
  申请人：UNIV RICE WILLIAM M

  公开号：WO2019036537A1

  公开（公告）日：2019-02-21

  In one aspect, the present disclosure provides trioxacarcin analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein as well as dimers of the compounds described herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.

  在一个方面，本公开提供了以下式的三氧环霉素类似物：其中变量如本文所定义。在另一个方面，本公开还提供了制备本文所披露的化合物以及本文所描述的二聚体的方法。在另一个方面，本公开还提供了药物组合物和使用本文所披露的化合物的方法。此外，还提供了具有化合物的细胞靶向基团的药物结合物。
• Synthesis of tetracyclines and analogues thereof
  申请人：President and Fellows of Harvard College

  公开号：US10669244B2

  公开（公告）日：2020-06-02

  The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.

  过去 50 年来，四环素类抗生素在治疗传染病方面发挥了重要作用。然而，随着四环素类药物在人类和兽医领域使用的增加，许多以前对四环素类抗生素易感的生物产生了抗药性。所述四环素和四环素类似物的模块化合成提供了一种高效的对映选择性途径，可获得以前通过早期的四环素合成和半合成方法无法获得的各种四环素类似物和多环化合物。这些类似物可用作治疗人类或其他动物疾病的抗微生物剂或抗增殖剂。
• SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF
  申请人：Myers Andrew G.

  公开号：US20110009371A1

  公开（公告）日：2011-01-13

  The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
• 5-AMINO-4-HYDROXYPENTOYL AMIDES
  申请人：Kalayanov Genadiy

  公开号：US20120295920A1

  公开（公告）日：2012-11-22

  HIV inhibitors of formula wherein R 1 is halo, C 1-4 alkoxy, trifluoromethoxy; n is 0 or 1; A is CH or N; R 5 and R 6 are hydrogen, C 1-4 alkyl, halo; R 7 and R 8 are C 1-4 alkyl or C 1-4 alkoxyC 1-4 alkyl; R 9 is C 1-4 alkyl, cyclopropyl, trifluoromethyl, C 1-4 alkoxy, or dimethylamino; R 10 is hydrogen, C 1-4 alkyl, cyclopropyl, trifluoromethyl, C 1-4 alkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.
• MYOSIN II ATPASE INHIBITOR COMPOUNDS
  申请人：DiSanto Michael E.

  公开号：US20170129886A1

  公开（公告）日：2017-05-11

  The present invention relates to Myosin II ATPase inhibitor compounds, including substituted 3a-hydroxy-1, 2, 3, 3a-tetrahydro-4H-pyrrolo [2,3b] quinolin-4-one compounds which are blebbistatin derivatives.